Avenue Biosciences
3 known investors
Avenue Biosciences operates a platform that engineers N-terminal signal peptides to modulate the secretory pathway and improve protein yield, combining high-throughput chemistry, synthetic biology, and machine learning. It targets therapeutic and biotechnology developers, optimizing expression across mammalian protein production systems including recombinant protein therapies, biosimilars, and cell and gene therapies.